We enrolled 38 patients who received pembrolizumab or nivolumab as second-line or later-line treatment for ESCC....Based on the expression levels of CD73 and PD-L1 (Figure 3), these patients were divided into four groups:...low expression levels of CD73/high expression levels of PD-L1 (Group C)....For 10 patients with partial response (PR), a higher PR rate (60%) was noted in the group C...patients in group C had better PFS than those in group B (p = 0.003)...a superior OS was found for group C compared to group B (p = 0.034)...better PFS and OS were found in patients with low expression levels of CD73 and high expression levels of PD-L1 compared to those with high expression levels of CD73 and low expression levels of PD-L1.